The average utility scores of metastatic and non-metastatic breast cancer patients in Vietnam were 0.79 and 0.89, higher than those of HER2-positive breast cancer patients in the United Kingdom (0.70 and 0.81), respectively [15]. This evidence concerns the gene ERBB2 and breast cancer.